|Bid||92.12 x 1100|
|Ask||92.82 x 1000|
|Day's Range||87.51 - 92.88|
|52 Week Range||32.30 - 111.90|
|Beta (5Y Monthly)||2.30|
|PE Ratio (TTM)||293.20|
|Earnings Date||Oct 26, 2020 - Oct 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||96.20|
Early signs of success with a revolutionary new type of cancer treatment make this biotech worth a closer look.
One analyst goes contrarian, raising her price target on the stock following some very dispiriting news from the company.
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.